Morepen manufactures Empagliflozin (API) in its US FDA-approved facilities and already has European DMF
Morepen Laboratories has launched Empamore, a game-changing treatment for Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF)and Chronic Kidney Disease (CKD).
Morepen manufactures Empagliflozin (API) in its US FDA-approved facilities and already has European DMF. The launch of Empamore reflects Morepen’s 40 years of pharmaceutical excellence, providing a cost-effective alternative to leading brands while ensuring affordability without compromising quality.
The product range includes:
Empagliflozin (Empamore 10mg/25mg)
Empagliflozin 12.5mg with Metformin 500/1000mg (Empamore M 500/1000mg)
Empagliflozin is a globally recognised SGLT2 inhibitor widely used for diabetes management. With pre-diabetes cases in India rising to nearly 136 million and the diabetes market expected to grow at a CAGR of 10.9 per cent, Morepen’s launch of Empamore comes at a crucial time to provide an affordable and effective solution.
